| Year 1 | Year 2 | |||
---|---|---|---|---|---|
 | 0–3 months | 3–6 months | 6–9 months | 9–12 months |  |
N with flare | 59/189 | 90/187 | 52/167 | 70/186 | 45/173 |
Age (years) | 56.0 (13.9) | 56.9 (13.0) | 59.5 (14.7) | 57.6 (13.2) | 57.1 (12.9) |
Disease duration (years) | 8.4 (8.6) | 8.4 (7.3) | 10.2 (9.8) * | 9.6 (9.3) | 8.8 (6.3) |
Baseline > 1 tophus | 16.9% | 14.4% | 19.2% | 24.3% * | 22.2% |
Co-morbidities (SCQ) sum | 4.6 (3.9) * | 4.0 (3.4) | 4.5 (3.4) | 4.5 (3.4)* | 3.8 (3.4) |
Baseline SUA | 502 (76) | 504 (76) | 498 (81) | 510 (38) | 504 (81) |
3 months SUA | 361 (76) * | 343 (62) | 339 (61) | 345 (60) | 351 (68) |
6 months SUA | 325 (65) | 328 (61) | 335 (63)* | 331 (63) | 331 (66) |
9 months SUA | 312 (54) | 317 (61) | 318 (69) | 328 (60) | 311 (58) |
12 months SUA | 304 (47) | 309 (46) | 299 (47) | 308 (48) | 313 (51) |
24 months SUA | 330 (80) | 331 (79) | 323 (68) | 337 (85) | 328 (67) |
Baseline allopurinol user (%) | 15.3% | 17.8% | 13.5% | 14.3% | 6.7% |
Month 3 allopurinol (mg) | 238 (86) | 239 (98) | 224 (105) | 253 (97)* | 228 (105) |
Month 6 allopurinol (mg) | 287 (98) | 275 (120) | 272 (134) | 308 (124)** | 275 (124) |
Month 9 allopurinol (mg) | 292 (128) | 281 (133) | 293 (145) | 307 (137)* | 291 (146) |
Month 12 allopurinol (mg) | 303 (126) | 295 (135) | 301 (146) | 333 (142)** | 292 (138) |
Ever use | |||||
 - NSAID | 87.5% | 79.3% | 80.4% | 88.1%* | 86.0% |
 - Colchicine | 52.7% | 60.0% | 57.7% | 67.7%* | 56.1% |
 - Prednisolone | 51.8% | 53.6% | 56.9% | 53.1% | 52.4% |
≥ 1 flare last 12 months | 82.5% | 82.4% | 88.5% | 77.6% | 90.5% |
> 5 previous flares | 59.6% | 56.8% | 63.5%* | 59.7% | 52.4%* |
Strongest pain ever | 8.7 (1.3)* | 8.5 (1.5) | 8.6 (1.2) | 8.7 (1.4) | 8.7 (1.1) |
Strongest pain last flare | 7.1 (2.0) | 7.2 (2.0) | 7.4 (2.0) | 7.1 (2.1) | 7.3 (1.9) |